Bio-Engine

Bio-Engine

Founded 2014 Series C Total: $300.00M Biopharma, Biotechnology +1

Bio-Engine is a biotech startup that was founded in 2014. The company specializes in developing advanced high-density serum-free suspension culture methods for animal cells. Its key offerings include HEK293 and PK15 cell serum-free media, which are designed for applications in antibodies, recombinant proteins, human and animal virus vaccines, and cell therapy. The startup operates in the biopharma, biotechnology, and manufacturing industries. In its latest funding round in May 15, 2023, Bio-Engine secured a significant investment of CNY300.00M in a Series C - Bio investment. The investment was made by a consortium of prominent investors including Qingsong Fund, Legend Capital, Riverhead Capital Investment Management, NRL Capital, Yipu Capital, Jianfa Xinxing Investment, Huimei Capital, and Ningbo Leo Capital. Bio-Engine's successful fundraising efforts and its focus on cutting-edge biotech solutions indicate the company's potential for significant growth and impact within the industry. Its innovative approach to cell culture and strategic partnerships with major investors position the company as a key player in the biotech and manufacturing sectors.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C Bio	CNY300.00M	9	Qingsong Fund, Legend Capital +7	15 May 2023
Series B Bio	Undisclosed	1	National SME Development Fund	27 Aug 2019
Series A Bio	Undisclosed	-		01 Jun 2018
Series A Bio	Undisclosed	-		01 Mar 2016

Funding Stage

Amount

Investors

Lead Investors

Date

Series C Bio

CNY300.00M

Qingsong Fund, Legend Capital +7

15 May 2023

Series B Bio

Undisclosed

National SME Development Fund

27 Aug 2019

Series A Bio

Undisclosed

01 Jun 2018

Series A Bio

Undisclosed

01 Mar 2016

FAQ About Bio-Engine

Bio-Engine specializes in developing advanced high-density serum-free suspension culture methods for animal cells. Key offerings include HEK293 and PK15 cell serum-free media, designed for applications in antibodies, recombinant proteins, human and animal virus vaccines, and cell therapy.

Bio-Engine was founded in 2014.

Bio-Engine operates in Biopharma, Biotechnology and Manufacturing.

Bio-Engine has completed 4 funding rounds, raising a total of $300.00M. The latest funding stage is Series C.

Top alternatives and competitors to Bio-Engine include 神州细胞工程有限公司, Wuhan Healthgen Biotechnology Corp., T&L Biotechnology, Mycenax Biotech Inc., StemImmune LLC. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Bio-Engine and 神州细胞工程有限公司 are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Bio-Engine

Funding Rounds & Investors (4)

Bio-Engine Alternatives & Competitors

FAQ About Bio-Engine